Cannabinoids – a class of lipophilic compounds that can activate either the cannabinoid CB1 or CB2 receptor – have shown potent anti-inflammatory effects. In a seminal study published in the journal Nature in 2005, the anti-atherosclerotic effect of low dose oral cannabinoids was clearly demonstrated in mice.  

 

However, research activity in this area has unfortunately been relatively subdued. This may be – in part – attributed to psychotropic side effects and poor bioavailability of orally administered cannabinoids. To overcome these limitations, nanoparticle formulations may offer an attractive alternative. In practice this means that the cannabinoids will be ‘packed’ in endogenous nanoparticles, offering the opportunity to effectively deliver these anti-atherosclerotic molecules to the diseased sites. 

 

Nanotechnology allows targeted delivery of cannabinoids and has the potential to elevate their use to scientifically validated therapeutic applications.